PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Immunization, Passive”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 325 records · Page 18Linked to original sources
PubMed1983

[Persistence of Mullerian ducts in the male rabbit by passive immunization against anti-mullerian hormone during fetal life].

A female Rabbit immunized against bovine anti-Müllerian hormone (AMH) was mated and gave birth to 3 litters, containing a total of 13 males. Ten of these presented with Müllerian derivatives, of variable development. Testicular position and structure, Wolffian development and virilization of the urogenital sinus were apparently normal in males with persistent Müllerian ducts.

Animals↗
PubMed1982

[Active and passive immunization against hepatitis B virus infection].

Immune serum globulin and hepatitis B immunoglobulin are used for prevention and prophylaxis in hepatitis B virus infection. These are effective against pre- and postexposure cases. Hepatitis B immunoglobulin is more effective than immune serum globulin. Hepatitis B virus vaccines are prepared from HBsAg and its polypeptides. The vaccines prevent from hepatitis B infection in a high percentage. Antibody response for HBsAg vaccines are about 95 percent. Hemodialysis units personnel and patients, surgeons, dentists, male homosexuals and infants in endemic areas must be vaccinated with HBsAg vaccines.

Adult↗
PubMed1977

[Passive immunization in heterakidosis].

The sera of Heterakis-infected birds influence the course of the infection caused by the parasite, lowering its survival rate and delaying the shed of its eggs. Sera containing higher amounts of gamma-globulins from five-month-old birds confer higher resistance even when applied on the 12th day of Heterakis infection to intact birds as compared to sera containing lower amounts of gamma-globulins from one-month-old birds when applied on the 30th day of infection. The drop of the survival rate of the Heterakis parasite in injecting the birds with sera from Heterakis-infected birds is due to the activation of the caecum response.

Age Factors↗
PubMed1996

Liver transplantation for hepatitis B cirrhosis: clinical sequela of passive immunization.

UNLABELLED: Aggressive administration of hepatitis B immune globulin (HBIg) has been shown to prevent hepatitis B viral (HBV) infection of the allograft; however, the clinical sequela of such therapy has not been previously described. We reviewed our experience with high dose, intravenous infusion of an intramuscular HBIg preparation to assess the effectiveness and complications of such therapy. Thirty three orthotopic liver transplants (OLTx) were performed in 32 patients with chronic HBV cirrhosis at the University of Virginia between March 1990 and June 1995. Twenty-nine of 32 (91%) patients remain free of HBV recurrence (defined by undetectable serum HBsAg and HBV-DNA) after a mean of 21 months (2-54 months), with one patient requiring retransplantation. Three (10%) patients died of non-HBV causes (two vascular events, one infectious event). Twenty episodes of acute cellular rejection were treated in 18 patients (two had two episodes). Sixteen rejections occurred within 18 d of transplant, 19 by day 120, and one late rejection occurred at 18 months owing to medication non-compliance. Eighteen patients had at least one documented infection. Six patients were treated for CMV infection (five empirically). Eight patients were treated for HSV infections (seven mild herpetic labialis and one herpetic keratitis). Four patients had documented fungal infection (one mucormycosis pneumonia and three minor superficial mucosal infections). With the exception of one necrotizing pneumonia, 11 bacterial infections were successfully treated with conventional antimicrobial agents. No patient developed post-transplant lymphoproliferative disorder. Symptoms associated with HBIg infusion were intermittent but frequent and consisted of myalgias, predominantly back pain (90%), headache (20%) and flushing (5%). No patient experienced anaphylaxis, fever, rash, arthritis or hypotension. Despite the potential for mercury toxicity and HCV transmission in the HBIg formulations currently available in the United States, serum mercury levels remained below standards for industrial exposure (60 micrograms/ml), and only one individual developed post-transplant HCV infection after receiving multiple units of unscreened blood prior to 1991. SUMMARY: High-dose HBIg prevented HBV infection of the allograft in 29 of 32 patients transplanted for HBV cirrhosis with three non-HBV associated deaths. The intravenous infusion of HBIg was frequently associated with minor side effects that were safely tolerated by patients. The risk of HCV transmission and mercury toxicity are minimal, but support the need for a new intravenous formulation of HBIg. HBIg therapy successfully decreased post-OLTx HBV recurrence with no clinical events associated with immunosuppression. Patients did non experience allergic or infusion-related complications that altered or terminated therapy. Manufacturing modifications of HBIg may allow for improved patient tolerance and decreased risks.

Adult↗
PubMed1996

Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

This report provides recommendations for use of the newly licensed hepatitis A vaccines (HAVRIX, manufactured by SmithKline Beecham Biologicals, and VAQTA, manufactured by Merck & Company, Inc.) in persons > or = 2 years of age and updates previous recommendations for use of immune globulin (IG) for protection against hepatitis A (superseding MMWR 1990;39[No. RR-2]:1-5). For preexposure protection, hepatitis A vaccine can now be used instead of IG in many circumstances; for postexposure prophylaxis, the recommendations for IG use are unchanged.

Adolescent↗